Indian pharmaceutical manufacturer Caplin Point Laboratories said that its wholly-owned subsidiary Caplin Sterlites Ltd signed a licence and supply agreement with US healthcare firm Baxter International for sales of five generic injectable drugs.
Under the agreement, Caplin will be supplying its products to Baxter for sales.
“All these ANDAs [generic drugs] have been developed in-house, and we’re keen to license them to Baxter, who have an excellent sales and marketing infrastructure in the US for commercialization of these products”, said Caplin.
Financial details were not revealed by the company.
Headquartered in Chennai, Caplin Point Laboratories caters predominantly to the Latin American and African markets. The company has received over 2,800 product approvals.
Deerfield, Illinois-based Baxter International focuses on products to treat hemophilia, kidney disease, immune disorders and other chronic and acute-medical conditions.